# Roivant Sciences (ROIV): value investors who own it

2 value investors held Roivant Sciences in their Q3 2026 13F, led by Greenlight Capital, Polen Capital Management.

## 13F holders

| Manager | Portfolio | Value | Change | Quarters held |
| --- | --- | --- | --- | --- |
| Greenlight Capital | 1.9% | $76.2m | Unchanged | 10 |
| Polen Capital Management | 0.0% | $306k | New | 1 |

## Directors buying and selling (Form 4, last 12 months)

| Date | Who | Role | Bought or sold | Shares | Value |
| --- | --- | --- | --- | --- | --- |
| 2026-10-01 | Epperly Melissa B, | Director | Sold | 16850 | $608k |
| 2026-10-01 | Epperly Melissa B, | Director | Sold | 900 | $33k |
| 2026-09-30 | Venker Eric | President & Immunovant CEO | Sold | 200000 | $7.3m |
| 2026-09-15 | Fitzgerald Meghan | Director | Sold | 4712 | $187k |
| 2026-09-15 | Epperly Melissa B, | Director | Sold | 4338 | $172k |
| 2026-09-15 | Epperly Melissa B, | Director | Sold | 600 | $24k |
| 2026-09-15 | Fitzgerald Meghan | Director | Sold | 400 | $16k |
| 2026-09-08 | Fitzgerald Meghan | Director | Sold | 20000 | $798k |
| 2026-08-28 | Venker Eric | President & Immunovant CEO | Sold | 166182 | $5.9m |
| 2026-08-28 | Venker Eric | President & Immunovant CEO | Sold | 33818 | $1.2m |
| 2026-08-21 | Sukhatme Mayukh | President & CIO | Sold | 144756 | $5.3m |
| 2026-08-20 | Sukhatme Mayukh | President & CIO | Sold | 17519 | $653k |
| 2026-08-19 | Sukhatme Mayukh | President & CIO | Sold | 172899 | $6.4m |
| 2026-08-18 | Sukhatme Mayukh | President & CIO | Sold | 105141 | $3.8m |
| 2026-08-18 | Sukhatme Mayukh | President & CIO | Sold | 31801 | $1.2m |
| 2026-08-17 | Sukhatme Mayukh | President & CIO | Sold | 284707 | $10.3m |
| 2026-08-14 | Sukhatme Mayukh | President & CIO | Sold | 243177 | $8.8m |
| 2026-07-27 | Venker Eric | President & Immunovant CEO | Sold | 200000 | $7.0m |

Source: SEC filings, via moatshark (https://www.moatshark.com/s/roiv). Values traded and returns are estimates. Not investment advice. Built 2026-10-21.